Chapter 33 — Anti-Cancer Drugs Part I Pharmacology — Module 3 — Antimetabolites: Folate Antagonists, Fluoropyrimidines, Cytidine and Purine Analogs, and Hypomethylating Agents
1. [CASE 1 — QUESTION 1]
A 17-year-old boy with high-grade osteosarcoma of the distal femur is admitted for a cycle of high-dose methotrexate (HD-MTX) with leucovorin rescue. His baseline renal function is normal, and he has no significant effusions. The oncology team reviews the pharmacology with the house staff before starting the infusion. As the first teaching point, the attending asks about the primary molecular target of methotrexate. Which enzyme does methotrexate directly inhibit?
A) Thymidylate synthase, the enzyme that converts deoxyuridine monophosphate to deoxythymidine monophosphate
B) Dihydrofolate reductase (DHFR), the enzyme that regenerates reduced tetrahydrofolate from dihydrofolate
C) Ribonucleotide reductase, the enzyme that converts ribonucleotides to deoxyribonucleotides
D) Xanthine oxidase, the enzyme that catabolizes purines to uric acid
E) DNA (deoxyribonucleic acid) methyltransferase 1, the maintenance methyltransferase
ANSWER: B
Rationale:
Methotrexate is a tight-binding competitive inhibitor of dihydrofolate reductase (DHFR), which regenerates reduced tetrahydrofolate. Depleting the reduced folate pool blocks thymidylate and purine synthesis and therefore DNA (deoxyribonucleic acid) synthesis, accounting for the drug's S-phase cytotoxicity in this osteosarcoma regimen.
Option B is correct because DHFR is the direct molecular target of methotrexate.
Option A: Option A is incorrect because thymidylate synthase is the target of fluoropyrimidines and pemetrexed; methotrexate inhibits it only indirectly through folate depletion.
Option C: Option C is incorrect because ribonucleotide reductase is inhibited by gemcitabine and hydroxyurea, not methotrexate.
Option D: Option D is incorrect because xanthine oxidase relates to purine catabolism and the thiopurine-allopurinol interaction, not methotrexate's mechanism.
Option E: Option E is incorrect because DNA methyltransferase 1 is the target of hypomethylating agents such as azacitidine and decitabine.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. The methotrexate infusion is completed, and leucovorin rescue is scheduled to begin at the protocol-specified interval afterward. A student asks why leucovorin protects normal cells without simply reversing the antitumor effect. What is the basis for leucovorin rescue?
A) Leucovorin inhibits xanthine oxidase, slowing methotrexate catabolism
B) Leucovorin enzymatically cleaves circulating methotrexate, lowering its plasma level
C) Leucovorin blocks methotrexate uptake equally in all cells, abolishing both toxicity and efficacy
D) Leucovorin is an already-reduced folate that enters the tetrahydrofolate pool downstream of the blocked dihydrofolate reductase, restoring folate-dependent synthesis in normal cells, which are relatively spared compared with tumor cells that retain more methotrexate polyglutamates
E) Leucovorin converts methotrexate into pemetrexed, a less toxic antifolate
ANSWER: D
Rationale:
Leucovorin (folinic acid) is a reduced folate that enters the tetrahydrofolate pool without requiring dihydrofolate reductase, bypassing the methotrexate block and restoring folate-dependent synthesis in normal cells. Tumor cells, which accumulate more methotrexate polyglutamates and have lower efflux, remain preferentially affected, so timed rescue protects normal tissue without fully negating antitumor effect.
Option D is correct because leucovorin supplies reduced folate downstream of the dihydrofolate reductase block, selectively rescuing normal cells.
Option A: Option A is incorrect because leucovorin does not inhibit xanthine oxidase or alter methotrexate catabolism.
Option B: Option B is incorrect because enzymatic cleavage of circulating methotrexate describes glucarpidase, not leucovorin.
Option C: Option C is incorrect because leucovorin does not block methotrexate uptake; it refills the downstream folate pool.
Option E: Option E is incorrect because leucovorin does not convert methotrexate into pemetrexed.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. At 48 hours the plasma methotrexate level is markedly elevated rather than falling toward the rescue threshold, and the serum creatinine has risen. The team reviews factors that prolong methotrexate exposure and the appropriate response. Which combination of measures is most appropriate?
A) Intensify leucovorin rescue guided by methotrexate levels, maintain vigorous hydration with urinary alkalinization, hold nephrotoxic and elimination-impairing drugs (NSAIDs [nonsteroidal anti-inflammatory drugs], proton pump inhibitors, penicillins), and consider glucarpidase to rapidly degrade circulating methotrexate
B) Stop leucovorin and observe, since rising levels indicate the rescue is no longer required
C) Administer allopurinol to lower the methotrexate concentration
D) Give additional bolus methotrexate to saturate renal transporters
E) Discontinue hydration to concentrate the urine and promote excretion
ANSWER: A
Rationale:
A markedly elevated 48-hour methotrexate level with rising creatinine signals delayed clearance with nephrotoxicity. Management intensifies leucovorin rescue guided by levels, sustains hydration with urinary alkalinization, removes drugs that impair renal methotrexate elimination (NSAIDs, proton pump inhibitors, penicillins), and considers glucarpidase to rapidly degrade circulating methotrexate.
Option A is correct because it bundles the established measures for delayed methotrexate clearance.
Option B: Option B is incorrect because leucovorin must be intensified, not stopped, when levels remain high.
Option C: Option C is incorrect because allopurinol does not lower methotrexate levels.
Option D: Option D is incorrect because additional methotrexate would worsen toxic exposure.
Option E: Option E is incorrect because stopping hydration would impair clearance and worsen nephrotoxicity.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. After recovery, the attending closes the teaching session by explaining why tumor cells are preferentially affected by methotrexate even though normal cells are rescued. Which intracellular process best accounts for this selectivity?
A) Tumor cells convert methotrexate to an inactive metabolite more slowly than normal cells, raising free drug
B) Tumor cells express more dihydrofolate reductase, which paradoxically increases their sensitivity
C) Folylpolyglutamate synthetase adds glutamate residues to methotrexate, trapping methotrexate polyglutamates intracellularly and increasing their affinity for folate-dependent enzymes; tumor cells that accumulate more polyglutamates and have lower efflux retain active drug longer and are preferentially killed
D) Tumor cells lack the reduced folate carrier, so they accumulate methotrexate by passive diffusion only
E) Tumor cells secrete leucovorin, protecting themselves from methotrexate
ANSWER: C
Rationale:
Polyglutamation by folylpolyglutamate synthetase adds charged glutamate residues that cannot cross the membrane, trapping methotrexate polyglutamates intracellularly and increasing their affinity for folate-dependent enzymes. Tumor cells that accumulate more polyglutamates and have lower efflux retain active drug longer, which underlies the selectivity exploited by high-dose methotrexate with timed leucovorin rescue.
Option C is correct because intracellular polyglutamate trapping with increased enzyme affinity explains preferential tumor effect.
Option A: Option A is incorrect because the selectivity is driven by polyglutamate retention, not slower inactivation of free drug.
Option B: Option B is incorrect because increased dihydrofolate reductase generally contributes to resistance, not enhanced sensitivity.
Option D: Option D is incorrect because methotrexate enters chiefly via the reduced folate carrier, and loss of that carrier reduces uptake rather than explaining selectivity.
Option E: Option E is incorrect because tumor cells do not secrete leucovorin to protect themselves.
5. [CASE 2 — QUESTION 1]
A 60-year-old woman with metastatic colorectal cancer begins a FOLFOX regimen that includes infusional 5-fluorouracil with leucovorin and oxaliplatin. During pre-treatment counseling the oncology fellow explains how leucovorin increases the efficacy of 5-fluorouracil at the level of its target enzyme. Which mechanism correctly describes this?
A) Leucovorin inhibits dihydropyrimidine dehydrogenase, slowing 5-fluorouracil catabolism and raising its level
B) Leucovorin rescues normal cells from 5-fluorouracil toxicity, exactly as it does with methotrexate
C) Leucovorin increases renal excretion of 5-fluorouracil, prolonging tumor exposure
D) Leucovorin converts 5-fluorouracil into capecitabine within the tumor
E) Leucovorin raises intracellular 5,10-methylenetetrahydrofolate, the folate cofactor that stabilizes the covalent ternary complex among FdUMP (fluorodeoxyuridine monophosphate), thymidylate synthase, and folate, deepening and prolonging thymidylate synthase inhibition
ANSWER: E
Rationale:
The active 5-fluorouracil metabolite FdUMP (fluorodeoxyuridine monophosphate) forms a covalent ternary complex with thymidylate synthase and the folate cofactor 5,10-methylenetetrahydrofolate. Leucovorin raises intracellular 5,10-methylenetetrahydrofolate, stabilizing the complex and deepening and prolonging thymidylate synthase inhibition, which increases tumor cell kill in colorectal cancer.
Option E is correct because leucovorin potentiates 5-fluorouracil by supplying the folate cofactor that stabilizes the ternary complex.
Option A: Option A is incorrect because leucovorin does not inhibit dihydropyrimidine dehydrogenase.
Option B: Option B is incorrect because with 5-fluorouracil leucovorin potentiates the drug rather than serving as a normal-cell rescue.
Option C: Option C is incorrect because leucovorin does not act by increasing renal excretion of 5-fluorouracil.
Option D: Option D is incorrect because leucovorin does not convert 5-fluorouracil into capecitabine.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. The regimen uses infusional rather than bolus 5-fluorouracil. The fellow asks the team to predict the predominant toxicity based on the schedule and the favored active metabolite. Which prediction is correct?
A) Sustained lower concentrations favor FdUMP (fluorodeoxyuridine monophosphate) and thymidylate synthase inhibition, so mucositis and hand-foot syndrome (palmar-plantar erythrodysesthesia) predominate over myelosuppression
B) Sustained lower concentrations favor FUTP (fluorouridine triphosphate) and RNA (ribonucleic acid) incorporation, so myelosuppression predominates
C) The schedule has no effect on which metabolite predominates, so the toxicity profile is random
E) Infusional dosing eliminates all 5-fluorouracil toxicity
ANSWER: A
Rationale:
Infusional (continuous) 5-fluorouracil maintains sustained, lower concentrations that favor FdUMP formation and thymidylate synthase inhibition, producing predominantly mucositis and hand-foot syndrome (palmar-plantar erythrodysesthesia). Bolus dosing produces high peaks that favor FUTP and RNA (ribonucleic acid) incorporation with predominant myelosuppression.
Option A is correct because infusional dosing shifts toxicity toward mucositis and hand-foot syndrome via thymidylate synthase inhibition.
Option B: Option B is incorrect because RNA incorporation and myelosuppression are favored by high-peak bolus dosing, not infusion.
Option C: Option C is incorrect because schedule does determine which metabolite predominates.
Option D: Option D is incorrect because cerebellar toxicity is a high-dose cytarabine effect, not a 5-fluorouracil effect.
Option E: Option E is incorrect because infusional dosing shifts, rather than eliminates, toxicity.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. Within the first week of the initial cycle she develops grade 4 neutropenia and thrombocytopenia, severe mucositis, profuse diarrhea, and neurotoxicity, far out of proportion to the dose administered. What is the most likely explanation and the appropriate response?
A) Expected toxicity of FOLFOX; continue at full dose and provide supportive care only
B) Oxaliplatin hypersensitivity; the 5-fluorouracil component is unaffected and should continue unchanged
C) Tumor lysis syndrome; give rasburicase and continue 5-fluorouracil
D) Dihydropyrimidine dehydrogenase (DPD) deficiency causing impaired 5-fluorouracil catabolism; stop the fluoropyrimidine immediately, provide intensive supportive care, and obtain DPYD genotyping or phenotypic DPD testing before any future fluoropyrimidine
E) Vitamin B12 deficiency; administer B12 and continue at full dose
ANSWER: D
Rationale:
Severe, early, multi-system toxicity disproportionate to dose within the first week of a fluoropyrimidine is the classic presentation of dihydropyrimidine dehydrogenase (DPD) deficiency, in which 5-fluorouracil cannot be catabolized. The fluoropyrimidine is stopped immediately, intensive supportive care is provided, and DPYD genotyping or phenotypic DPD testing guides any future therapy.
Option D is correct because the disproportionate early multi-system toxicity indicates DPD deficiency and mandates stopping the drug and testing.
Option A: Option A is incorrect because this is severe, potentially fatal toxicity, not expected toxicity to continue through.
Option B: Option B is incorrect because the picture is fluoropyrimidine-related; attributing it to oxaliplatin and continuing 5-fluorouracil would be dangerous.
Option C: Option C is incorrect because the presentation is fluoropyrimidine toxicity, not tumor lysis syndrome.
Option E: Option E is incorrect because B12 deficiency does not explain this presentation, and continuing full-dose fluoropyrimidine in DPD deficiency is hazardous.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. After recovery and DPD-guided dose individualization, she is later transitioned to oral capecitabine for ongoing therapy. She also takes warfarin for atrial fibrillation, with a previously stable international normalized ratio (INR). Two weeks after starting capecitabine, her INR rises sharply. What is the mechanism and the appropriate management?
A) Capecitabine induces CYP2C9, increasing warfarin clearance; the warfarin dose should be increased
B) The change is unrelated to capecitabine; both drugs should continue unchanged
C) Capecitabine inhibits CYP2C9 (cytochrome P450 2C9), reducing clearance of the more potent S-warfarin enantiomer and raising the INR; hold warfarin, manage the elevated INR per protocol, monitor frequently, and resume at a substantially lower dose or transition to a direct oral anticoagulant that is not CYP2C9-dependent
D) Capecitabine chelates vitamin K, and the solution is high-dose oral vitamin K with continued full-dose warfarin
E) Capecitabine causes malabsorption of warfarin, so warfarin should be given at a higher dose
ANSWER: C
Rationale:
Capecitabine inhibits CYP2C9 (cytochrome P450 2C9), reducing clearance of the more potent S-warfarin enantiomer and raising the INR, often within one to two weeks. Warfarin is held, the elevated INR is managed per protocol, monitoring is intensified, and warfarin is resumed at a substantially lower dose or replaced by a direct oral anticoagulant not dependent on CYP2C9.
Option C is correct because it identifies CYP2C9 inhibition of S-warfarin and applies appropriate management.
Option A: Option A is incorrect because capecitabine inhibits rather than induces CYP2C9, so increasing warfarin would worsen over-anticoagulation.
Option B: Option B is incorrect because the interaction is well described and the elevated INR requires action.
Option D: Option D is incorrect because the mechanism is CYP2C9 inhibition, not vitamin K chelation, and continued full-dose warfarin would be unsafe.
Option E: Option E is incorrect because the mechanism is metabolic inhibition, not malabsorption, and raising the warfarin dose would further increase the INR.
9. [CASE 3 — QUESTION 1]
A 58-year-old man with newly diagnosed acute myeloid leukemia (AML) is admitted for "7+3" induction with a 7-day continuous infusion of cytarabine plus 3 days of an anthracycline. During rounds, the team reviews how cytarabine becomes cytotoxic. Which statement correctly describes its activation and mechanism?
A) Cytarabine inhibits dihydrofolate reductase after passive diffusion into cells
B) Cytarabine enters cells via nucleoside transporters and is phosphorylated, the rate-limiting step being deoxycytidine kinase (dCK), to ara-CTP (cytarabine triphosphate), which is incorporated into DNA (deoxyribonucleic acid) and produces chain termination during S phase
C) Cytarabine is a prodrug converted to 5-fluorouracil by thymidine phosphorylase
D) Cytarabine acts mainly by trapping DNA (deoxyribonucleic acid) methyltransferase 1 and demethylating promoters
E) Cytarabine inhibits ribonucleotide reductase as its sole mechanism without DNA incorporation
ANSWER: B
Rationale:
Cytarabine enters cells through nucleoside transporters and is phosphorylated to its active triphosphate ara-CTP (cytarabine triphosphate); the rate-limiting activation step is deoxycytidine kinase (dCK). Ara-CTP is incorporated into DNA (deoxyribonucleic acid) and produces chain termination, and because DNA polymerases act in S phase, cytarabine is S-phase-specific, the basis for the continuous-infusion schedule.
Option B is correct because it accurately describes dCK-limited activation and S-phase DNA chain termination.
Option A: Option A is incorrect because cytarabine does not inhibit dihydrofolate reductase.
Option C: Option C is incorrect because cytarabine is not a 5-fluorouracil prodrug; that describes capecitabine.
Option D: Option D is incorrect because DNA methyltransferase trapping describes hypomethylating agents, not cytarabine.
Option E: Option E is incorrect because ribonucleotide reductase inhibition is a gemcitabine feature, and cytarabine acts chiefly through DNA incorporation and chain termination.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. A student asks why cytarabine is given as a 7-day continuous infusion rather than as a single daily bolus. Integrating its S-phase specificity with leukemic blast kinetics, which explanation is correct?
A) Because only a fraction of blasts are in S phase at any moment, a sustained cytotoxic concentration over 7 days exposes each blast to drug as it cycles into S phase, whereas a bolus would spare cells entering S phase after the drug cleared
B) Because cytarabine is cell-cycle-nonspecific, the schedule is arbitrary and only total dose matters
C) Because all leukemic blasts are simultaneously in S phase, a single bolus reaches every cell at once
D) Because continuous infusion converts cytarabine into a cell-cycle-nonspecific agent that kills resting cells
E) Because the infusion is used solely to reduce nausea, with no pharmacologic rationale
ANSWER: A
Rationale:
Cytarabine is S-phase-specific, and at any instant only a fraction of leukemic blasts are in S phase. A 7-day continuous infusion maintains a cytotoxic concentration so that each blast is exposed as it cycles into S phase, whereas a bolus would miss cells entering S phase after the drug cleared. This kinetic rationale underlies the "7+3" schedule.
Option A is correct because sustained exposure covers blasts as they enter S phase over the treatment window.
Option B: Option B is incorrect because cytarabine is S-phase-specific, so schedule matters.
Option C: Option C is incorrect because blasts are not all simultaneously in S phase.
Option D: Option D is incorrect because infusion does not make cytarabine cell-cycle-nonspecific or enable killing of resting cells.
Option E: Option E is incorrect because the schedule has a clear cell-cycle pharmacologic rationale, not merely an antiemetic one.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. He achieves remission and proceeds to consolidation with high-dose cytarabine (HiDAC). On day 4 of a HiDAC cycle he develops gait ataxia, dysarthria, and nystagmus; his renal function has declined during the admission. What is the correct interpretation and action?
A) Expected gastrointestinal toxicity; continue HiDAC and add an antiemetic
B) Anxiety-related symptoms; proceed with the next dose
C) Presumed cytarabine resistance; increase the dose
D) Cytarabine cerebellar neurotoxicity from Purkinje cell injury, with older age and renal impairment as key risk factors; perform neurologic assessment before each dose and discontinue cytarabine immediately when cerebellar signs appear, as continued dosing risks irreversible damage
E) Anthracycline cardiotoxicity; stop the anthracycline only and continue cytarabine unchanged
ANSWER: D
Rationale:
Ataxia, dysarthria, and nystagmus during high-dose cytarabine indicate cerebellar neurotoxicity from Purkinje cell injury, with older age and renal impairment as principal risk factors. Neurologic assessment precedes each dose, and the appearance of cerebellar signs mandates immediate discontinuation because continued dosing risks irreversible cerebellar damage.
Option D is correct because the cerebellar syndrome requires immediate cessation of cytarabine.
Option A: Option A is incorrect because these are central cerebellar signs, not gastrointestinal effects.
Option B: Option B is incorrect because objective cerebellar signs cannot be dismissed as anxiety.
Option C: Option C is incorrect because increasing the dose would worsen the neurotoxicity.
Option E: Option E is incorrect because the cerebellar findings reflect cytarabine toxicity, not anthracycline cardiotoxicity, and continuing cytarabine would be unsafe.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. Months later his leukemia relapses and appears refractory to cytarabine-based therapy. The team discusses the most likely pharmacologic basis for cytarabine resistance. Which mechanism is the primary cause?
A) Amplification of dihydrofolate reductase
B) Increased reduced folate carrier expression
C) Loss of thymidylate synthase activity
D) Overexpression of DNA (deoxyribonucleic acid) methyltransferase 1
E) Loss of deoxycytidine kinase (dCK) activity, the rate-limiting activating enzyme, with additional contributions from increased cytidine deaminase (CDA)-mediated catabolism and reduced hENT1 (human equilibrative nucleoside transporter 1) uptake
ANSWER: E
Rationale:
The primary mechanism of cytarabine resistance is loss of deoxycytidine kinase (dCK) activity, the rate-limiting activating enzyme, so the drug cannot be converted to ara-CTP. Increased cytidine deaminase (CDA)-mediated catabolism to inactive ara-U and reduced hENT1 (human equilibrative nucleoside transporter 1) uptake further limit intracellular active drug.
Option E is correct because loss of dCK is the chief cause, with CDA and hENT1 contributing.
Option A: Option A is incorrect because dihydrofolate reductase amplification causes methotrexate resistance, not cytarabine resistance.
Option B: Option B is incorrect because the reduced folate carrier transports antifolates, not cytarabine; increased expression would not cause cytarabine resistance.
Option C: Option C is incorrect because thymidylate synthase is unrelated to cytarabine activation.
Option D: Option D is incorrect because DNA methyltransferase 1 overexpression does not explain cytarabine resistance.
13. [CASE 4 — QUESTION 1]
A 69-year-old man with metastatic pancreatic adenocarcinoma begins gemcitabine-based therapy. The oncology fellow explains why gemcitabine incorporates into DNA (deoxyribonucleic acid) especially efficiently through a self-reinforcing mechanism. Which sequence is correct?
A) Gemcitabine inhibits thymidylate synthase, depleting thymidylate and stopping the cell cycle independently of incorporation
B) Gemcitabine raises the dCTP (deoxycytidine triphosphate) pool, increasing competition and reducing its own incorporation
C) Gemcitabine inhibits dihydrofolate reductase, increasing the folate pool
D) Gemcitabine inhibits cytidine deaminase, preventing its own catabolism and thereby increasing incorporation
E) Gemcitabine diphosphate inhibits ribonucleotide reductase, lowering the dCTP (deoxycytidine triphosphate) pool; with less competing dCTP at DNA (deoxyribonucleic acid) polymerase, gemcitabine triphosphate is incorporated more efficiently, a self-potentiating loop
ANSWER: E
Rationale:
Gemcitabine diphosphate inhibits ribonucleotide reductase, lowering the deoxycytidine triphosphate (dCTP) pool. Because dCTP competes with gemcitabine triphosphate at DNA (deoxyribonucleic acid) polymerase, less dCTP means less competition and more efficient incorporation of gemcitabine triphosphate, a self-potentiating loop unique among the cytidine analogs.
Option E is correct because it traces ribonucleotide reductase inhibition to a lower dCTP pool and enhanced incorporation.
Option A: Option A is incorrect because gemcitabine does not act through thymidylate synthase.
Option B: Option B is incorrect because ribonucleotide reductase inhibition lowers, not raises, the dCTP pool.
Option C: Option C is incorrect because gemcitabine does not inhibit dihydrofolate reductase.
Option D: Option D is incorrect because gemcitabine is a substrate, not an inhibitor, of cytidine deaminase, and self-potentiation works through reduced dCTP competition.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. The fellow contrasts gemcitabine with cytarabine in how each terminates DNA (deoxyribonucleic acid) chain elongation after incorporation. Which statement is correct?
A) Both produce immediate, overt chain termination at the point of incorporation
B) Both produce masked chain termination, allowing one further nucleotide before stopping
C) Cytarabine produces immediate (overt) chain termination, whereas gemcitabine permits one additional nucleotide before terminating (masked chain termination), which makes incorporated gemcitabine relatively resistant to proofreading exonucleases
D) Cytarabine permits one additional nucleotide before terminating, whereas gemcitabine blocks elongation immediately
E) Neither terminates the chain; both act solely by inhibiting thymidylate synthase
ANSWER: C
Rationale:
Once incorporated, cytarabine produces an immediate, overt steric block to elongation, whereas gemcitabine permits addition of one further nucleotide before elongation stops (masked chain termination), which renders incorporated gemcitabine relatively resistant to proofreading exonucleases. This contrast is a defining pharmacologic difference between the two cytidine analogs.
Option C is correct because it correctly assigns overt termination to cytarabine and masked termination to gemcitabine.
Option A: Option A is incorrect because gemcitabine produces masked, not immediate, termination.
Option B: Option B is incorrect because cytarabine produces overt, not masked, termination.
Option D: Option D is incorrect because it reverses the two behaviors.
Option E: Option E is incorrect because both agents do terminate DNA chain elongation and do not act solely through thymidylate synthase inhibition.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. During the second cycle he develops progressive dyspnea and hypoxemia, and chest imaging shows bilateral interstitial infiltrates; infection and cardiac failure are reasonably excluded. What is the most likely cause and the appropriate action?
A) Expected flu-like syndrome of gemcitabine; give acetaminophen and continue at full dose without further evaluation
B) Gemcitabine pulmonary toxicity (drug-induced interstitial lung disease); hold gemcitabine and provide supportive care, with corticosteroids in severe cases
C) Cerebellar toxicity of gemcitabine; reduce the dose and continue
D) Hand-foot syndrome involving the lungs; apply topical therapy and continue
E) Hemolytic uremic syndrome; the infiltrates indicate microangiopathy and require plasma exchange
ANSWER: B
Rationale:
Gemcitabine can cause a characteristic pulmonary toxicity presenting as dyspnea, hypoxemia, and interstitial infiltrates, usually within the first few cycles, after infection and cardiac causes are excluded. Management is to hold gemcitabine and provide supportive care, with corticosteroids for severe drug-induced interstitial lung disease.
Option B is correct because the presentation is classic gemcitabine pulmonary toxicity requiring drug cessation and supportive care.
Option A: Option A is incorrect because progressive dyspnea with infiltrates is not the benign flu-like syndrome and warrants evaluation and drug cessation.
Option C: Option C is incorrect because gemcitabine does not characteristically cause cerebellar toxicity, and the findings are pulmonary.
Option D: Option D is incorrect because hand-foot syndrome is a cutaneous palmar-plantar reaction and does not produce pulmonary infiltrates.
Option E: Option E is incorrect because hemolytic uremic syndrome presents with microangiopathic hemolysis, thrombocytopenia, and acute kidney injury, not isolated interstitial infiltrates.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. After the pulmonary episode resolves and therapy is later resumed, he develops new fatigue and dark urine. Labs show anemia with schistocytes (microangiopathic hemolytic anemia), thrombocytopenia, elevated lactate dehydrogenase with low haptoglobin, and rising creatinine; coagulation studies are near normal. What is the diagnosis and the immediate action regarding the drug?
A) Disseminated intravascular coagulation; continue gemcitabine and give fresh frozen plasma
B) Iron deficiency anemia; continue gemcitabine and start oral iron
C) Autoimmune hemolytic anemia from gemcitabine; continue the drug with corticosteroids
D) Gemcitabine-induced hemolytic uremic syndrome (a thrombotic microangiopathy); discontinue gemcitabine immediately and provide supportive care
E) Expected myelosuppression; continue gemcitabine and transfuse as needed
ANSWER: D
Rationale:
Microangiopathic hemolytic anemia (schistocytes), thrombocytopenia, and acute kidney injury with near-normal coagulation in a patient on gemcitabine indicate gemcitabine-induced hemolytic uremic syndrome, a thrombotic microangiopathy. Although rare, it is potentially fatal, and the essential action is immediate discontinuation of gemcitabine with supportive care.
Option D is correct because the triad with preserved coagulation defines a thrombotic microangiopathy requiring drug cessation.
Option A: Option A is incorrect because near-normal coagulation argues against disseminated intravascular coagulation, and continuing gemcitabine would be harmful.
Option B: Option B is incorrect because schistocytes, thrombocytopenia, and acute kidney injury are not iron deficiency.
Option C: Option C is incorrect because the microangiopathic picture is a thrombotic microangiopathy requiring discontinuation, not an autoimmune hemolytic anemia managed by continuing the drug.
Option E: Option E is incorrect because this is a specific thrombotic microangiopathy, not routine myelosuppression to be managed by transfusion while continuing the drug.
17. [CASE 5 — QUESTION 1]
A 7-year-old girl in the maintenance phase of acute lymphoblastic leukemia (ALL) therapy is treated with daily oral 6-mercaptopurine (6-MP). The team reviews how 6-mercaptopurine is activated and inactivated. Which statement correctly describes its metabolism?
A) 6-Mercaptopurine is activated by HGPRT (hypoxanthine-guanine phosphoribosyltransferase) to thioguanine nucleotides (TGNs) that are incorporated into DNA (deoxyribonucleic acid), and it is inactivated by two routes: methylation by thiopurine methyltransferase (TPMT) and oxidation by xanthine oxidase (XO)
B) 6-Mercaptopurine is activated by deoxycytidine kinase and inactivated by cytidine deaminase
C) 6-Mercaptopurine inhibits dihydrofolate reductase and is cleared unchanged by the kidney
D) 6-Mercaptopurine is a prodrug converted to 5-fluorouracil by thymidine phosphorylase
E) 6-Mercaptopurine traps DNA (deoxyribonucleic acid) methyltransferase 1 and acts as a hypomethylating agent
ANSWER: A
Rationale:
6-Mercaptopurine is activated by HGPRT (hypoxanthine-guanine phosphoribosyltransferase) to thioguanine nucleotides (TGNs) incorporated into DNA (deoxyribonucleic acid). Its two inactivation routes are methylation by thiopurine methyltransferase (TPMT) and oxidation by xanthine oxidase (XO), which together determine its dosing safety.
Option A is correct because it accurately describes HGPRT activation and the TPMT and xanthine oxidase inactivation routes.
Option B: Option B is incorrect because deoxycytidine kinase and cytidine deaminase act on cytidine analogs, not thiopurines.
Option C: Option C is incorrect because 6-mercaptopurine does not inhibit dihydrofolate reductase and is not cleared unchanged renally.
Option D: Option D is incorrect because 6-mercaptopurine is not a 5-fluorouracil prodrug.
Option E: Option E is incorrect because 6-mercaptopurine is not a hypomethylating agent and does not trap DNA methyltransferase 1.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient. Two weeks after starting standard-dose 6-mercaptopurine she develops profound pancytopenia and severe mucositis. Pretreatment thiopurine pharmacogenomic testing had not been performed. Which finding best explains this, and what does it imply for dosing?
A) High (wild-type) thiopurine methyltransferase activity; the dose should be increased
B) DPYD deficiency; 6-mercaptopurine dosing is unaffected and should continue unchanged
C) Low or absent thiopurine methyltransferase (TPMT) activity, causing marked thioguanine nucleotide accumulation; 6-mercaptopurine must be drastically reduced (commonly to roughly 10 to 20% of standard) or held, with TPMT-guided dosing thereafter
D) UGT1A1 polymorphism; this explains the toxicity and requires no dose change
E) Normal metabolism; this degree of toxicity is expected at standard dosing
ANSWER: C
Rationale:
Profound early myelosuppression at standard 6-mercaptopurine dosing is the hallmark of low or absent thiopurine methyltransferase (TPMT) activity, which impairs methylation and shunts drug toward toxic thioguanine nucleotide accumulation. Such patients require drastic dose reduction (commonly to roughly 10 to 20% of standard) or holding, with TPMT genotype- or phenotype-guided dosing thereafter.
Option C is correct because low TPMT activity explains the severe toxicity and mandates a large dose reduction.
Option A: Option A is incorrect because high (wild-type) activity would not cause this toxicity, and increasing the dose would be dangerous.
Option B: Option B is incorrect because DPYD deficiency governs fluoropyrimidine, not thiopurine, toxicity.
Option D: Option D is incorrect because UGT1A1 polymorphism relates to irinotecan toxicity, not 6-mercaptopurine myelosuppression.
Option E: Option E is incorrect because this severe pancytopenia is not the expected effect of standard dosing.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient. After recovery and TPMT-guided dosing, she later develops hyperuricemia, and a consulting clinician proposes starting standard-dose allopurinol. Integrating the thiopurine inactivation pathways, what is the safest approach?
A) Start standard-dose allopurinol with no change to the thiopurine, as there is no meaningful interaction
B) Recognize that allopurinol inhibits xanthine oxidase, a major catabolic route for 6-mercaptopurine, and either reduce the thiopurine dose to approximately 25% with close blood-count monitoring or manage the urate problem with an alternative such as rasburicase instead of allopurinol
C) Increase the thiopurine dose to maintain disease control while on allopurinol
D) Permanently discontinue the thiopurine, since any allopurinol exposure is invariably fatal
E) Add leucovorin to neutralize the interaction and continue both at full dose
ANSWER: B
Rationale:
Allopurinol inhibits xanthine oxidase, a major catabolic route for 6-mercaptopurine; blocking it raises thiopurine levels several-fold and risks fatal myelosuppression. The safe approach is to reduce the thiopurine dose to approximately 25% with close monitoring when allopurinol is unavoidable, or to manage urate with an alternative such as rasburicase. The danger is heightened here given her already-low TPMT activity.
Option B is correct because dose reduction with monitoring or substituting rasburicase addresses the xanthine oxidase interaction.
Option A: Option A is incorrect because the interaction is real and potentially fatal.
Option C: Option C is incorrect because increasing the dose would worsen toxicity given reduced catabolism.
Option D: Option D is incorrect because the combination can be managed with dose reduction; permanent discontinuation is not mandatory.
Option E: Option E is incorrect because leucovorin does not counteract this thiopurine-xanthine oxidase interaction.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient. Later in her course, leukemic cells appear resistant to thiopurine therapy. The team reviews the principal mechanisms of thiopurine resistance. Which mechanism is most directly responsible for failure of 6-mercaptopurine to form its active nucleotides?
A) Amplification of dihydrofolate reductase
B) Increased reduced folate carrier expression
C) Overexpression of thymidylate synthase
D) Loss of HGPRT (hypoxanthine-guanine phosphoribosyltransferase) activity, the activating enzyme required to convert 6-mercaptopurine to thioguanine nucleotides; loss of mismatch repair (MMR) can additionally blunt the apoptotic response to incorporated thioguanine
6-Mercaptopurine requires activation by HGPRT (hypoxanthine-guanine phosphoribosyltransferase) to form thioguanine nucleotides; loss of HGPRT activity prevents activation and is a principal thiopurine resistance mechanism. Loss of mismatch repair (MMR) can further blunt the apoptotic response triggered by incorporated thioguanine, contributing to resistance.
Option D is correct because loss of the activating enzyme HGPRT directly prevents thiopurine activation, with MMR loss as an additional contributor.
Option A: Option A is incorrect because dihydrofolate reductase amplification causes methotrexate resistance.
Option B: Option B is incorrect because the reduced folate carrier transports antifolates, not thiopurines.
Option C: Option C is incorrect because thymidylate synthase overexpression relates to fluoropyrimidine and pemetrexed resistance.
Option E: Option E is incorrect because hENT1 governs cytidine analog uptake, not thiopurine activation.
21. [CASE 6 — QUESTION 1]
A 66-year-old man with chronic lymphocytic leukemia (CLL) and favorable-risk disease begins an FCR regimen (fludarabine, cyclophosphamide, rituximab). The team discusses fludarabine's principal long-term immunologic effect and the prophylaxis it necessitates. Which statement is correct?
A) Fludarabine has no clinically important effect on lymphocytes, so no prophylaxis is required
B) Fludarabine causes isolated neutropenia only, so broad-spectrum antibacterial prophylaxis alone is sufficient
C) Fludarabine primarily causes anemia, so iron and erythropoietin are the key supportive measures
D) Fludarabine causes a transient rise in CD4 (cluster of differentiation 4) T cells, which protects against opportunistic infection
E) Fludarabine produces profound, sustained depletion of CD4 (cluster of differentiation 4) T-helper lymphocytes lasting months to years, predisposing to opportunistic infections; Pneumocystis jirovecii pneumonia (PCP) prophylaxis (typically trimethoprim-sulfamethoxazole) plus antiviral prophylaxis against herpesvirus reactivation is indicated during and for months after therapy
ANSWER: E
Rationale:
Fludarabine produces profound, sustained depletion of CD4 (cluster of differentiation 4) T-helper lymphocytes lasting months to years, impairing cell-mediated immunity and predisposing to opportunistic infections. This necessitates Pneumocystis jirovecii pneumonia (PCP) prophylaxis (commonly trimethoprim-sulfamethoxazole) plus antiviral prophylaxis against herpesvirus reactivation during and for months after therapy.
Option E is correct because it accurately describes the CD4 depletion and the matching opportunistic-infection prophylaxis.
Option A: Option A is incorrect because fludarabine has a major effect on lymphocytes requiring prophylaxis.
Option B: Option B is incorrect because the principal deficit is in cell-mediated immunity, not isolated neutropenia.
Option C: Option C is incorrect because the characteristic effect is T-cell depletion with infection risk, not primarily anemia.
Option D: Option D is incorrect because fludarabine depletes rather than raises CD4 T cells.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient. Partway through therapy he develops worsening fatigue and jaundice, with a falling hemoglobin, elevated lactate dehydrogenase, low haptoglobin, spherocytes, and a positive direct antiglobulin test (DAT). What is the most appropriate action regarding the fludarabine?
A) Recognize fludarabine-associated autoimmune hemolytic anemia (AIHA) and discontinue fludarabine immediately, since continuation worsens hemolysis; treat the AIHA (for example, with corticosteroids) as indicated
B) Continue fludarabine and transfuse, since the hemolysis is unrelated to therapy
C) Increase the fludarabine dose to suppress the autoimmune process faster
D) Add allopurinol, which reverses fludarabine-associated hemolysis
E) Switch to cladribine, which carries no risk of immune complications
ANSWER: A
Rationale:
A warm autoimmune hemolytic anemia (positive direct antiglobulin test, spherocytes, elevated lactate dehydrogenase, low haptoglobin) arising during fludarabine therapy in chronic lymphocytic leukemia is a recognized complication. Its development is an indication to discontinue fludarabine immediately, because continuation worsens hemolysis; the autoimmune hemolytic anemia is then treated, for example with corticosteroids.
Option A is correct because immediate discontinuation plus treatment of the autoimmune hemolytic anemia is the established response.
Option B: Option B is incorrect because the hemolysis is drug-associated and continuing fludarabine is harmful.
Option C: Option C is incorrect because increasing the dose would worsen the autoimmune hemolysis.
Option D: Option D is incorrect because allopurinol does not reverse fludarabine-associated hemolysis.
Option E: Option E is incorrect because cladribine is also a purine analog causing profound immunosuppression and is not a safe automatic substitute; the priority is stopping the offending drug.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient. Years later he develops a therapy-related myelodysplastic syndrome (MDS) and is started on azacitidine. After two cycles there is no count improvement, and the covering team proposes stopping for "treatment failure." Integrating the drug's mechanism, what is the best recommendation?
A) Stop azacitidine now, since absence of response after two cycles proves resistance
B) Switch immediately to intensive induction chemotherapy because the hypomethylating agent has failed
C) Continue azacitidine: it acts by trapping and depleting DNA (deoxyribonucleic acid) methyltransferase 1 (DNMT1), producing passive demethylation that accumulates only across successive cell divisions, so a minimum of four to six cycles is generally needed before declaring failure when tolerance permits
D) Add allopurinol to potentiate azacitidine and continue
E) Declare failure and move to best supportive care only
ANSWER: C
Rationale:
Azacitidine traps and depletes DNA (deoxyribonucleic acid) methyltransferase 1 (DNMT1), producing passive demethylation that accumulates only across successive cell divisions; reactivating silenced tumor suppressor genes therefore requires multiple cycles, with responses often emerging between cycles four and six. Stopping after two cycles in a tolerating patient risks aborting a response that has not yet developed, so a minimum of four to six cycles is recommended before declaring failure.
Option C is correct because the demethylation mechanism requires four to six cycles before failure can be declared.
Option A: Option A is incorrect because two cycles is too early to conclude resistance with this mechanism.
Option B: Option B is incorrect because switching to intensive induction is not warranted before an adequate hypomethylating-agent trial.
Option D: Option D is incorrect because allopurinol does not potentiate azacitidine and carries interaction risks.
Option E: Option E is incorrect because moving to supportive care only is premature before an adequate four-to-six-cycle trial.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient. The team considers switching from azacitidine to decitabine and reviews how the two hypomethylating agents differ structurally and in where they are incorporated. Which statement correctly distinguishes them?
A) Decitabine is a ribonucleoside incorporated into both RNA (ribonucleic acid) and DNA (deoxyribonucleic acid); azacitidine is incorporated only into DNA
B) Azacitidine is a ribonucleoside incorporated into both RNA (ribonucleic acid) and DNA (deoxyribonucleic acid), adding RNA-directed effects; decitabine is a deoxyribonucleoside incorporated exclusively into DNA, focusing its DNMT1 (DNA methyltransferase 1) trapping and demethylating effect
C) Both are ribonucleosides incorporated only into RNA (ribonucleic acid)
D) Both are deoxyribonucleosides incorporated only into DNA (deoxyribonucleic acid)
E) Neither is incorporated into nucleic acids; both act purely by extracellular enzyme inhibition
ANSWER: B
Rationale:
Azacitidine is a ribonucleoside incorporated into both RNA (ribonucleic acid) and, after reduction, DNA (deoxyribonucleic acid), adding RNA-directed effects such as disruption of RNA processing. Decitabine is a deoxyribonucleoside incorporated exclusively into DNA, which focuses its DNMT1 (DNA methyltransferase 1) trapping and demethylating effect.
Option B is correct because azacitidine is the ribonucleoside (RNA and DNA) and decitabine the deoxyribonucleoside (DNA only).
Option A: Option A is incorrect because it reverses the two agents.
Option C: Option C is incorrect because decitabine is incorporated into DNA and azacitidine enters DNA as well as RNA.
Option D: Option D is incorrect because azacitidine is a ribonucleoside with RNA incorporation, not a DNA-only deoxyribonucleoside.
Option E: Option E is incorrect because both agents are incorporated into nucleic acids and trap DNMT1 on DNA.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.